Navidea Biopharmaceuticals Inc. (AMEX:NAVB) has a beta of 1.11. The stock’s Relative Strength Index (RSI) is 86.47, with weekly volatility at 17.94% and ATR at 0.13. The NAVB stock’s 52-week price range has touched low of $0.49 and a $1.81 high. Its shares traded higher over the last trading session, gaining 87.91% on 05/21/20. The shares fell to a low of $1.20 before closing at $2.39. Intraday shares traded counted 44.69 million, which was -27709.65% lower than its 30-day average trading volume of 160.70K. NAVB’s previous close was $1.27 while the outstanding shares total 18.33M.
Investors have identified the Biotechnology company Navidea Biopharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $22.75 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Navidea Biopharmaceuticals Inc. (NAVB) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 3447000 million total, with 4355000 million as their total liabilities.
NAVB were able to record -0.95 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -0.45 million. In cash movements, the company had a total of -0.95 million as operating cash flow.
Potential earnings growth for Navidea Biopharmaceuticals Inc. (NAVB)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Navidea Biopharmaceuticals Inc. recorded a total of 0.16 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 73.08% coming in sequential stages and their sales for the third quarter increasing by 23.72%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.0 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.16 million. This allows shareholders to hold on to 18.33M with the revenue now reading -0.13 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter.
Having a look at the company’s valuation, the company is expected to record -0.76 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NAVB sounds very interesting.
Is the stock of NAVB attractive?
In related news, CEO, COO & CFO, Latkin Jed bought 5,000 shares of the company’s stock in a transaction that recorded on Feb 20. The purchase was performed at an average price of 1.08, for a total value of 5,400. As the purchase deal closes, the 10% Owner, Scott John K Jr. now bought 2,373,529 shares of the company’s stock, valued at 2,017,500. Also, 10% Owner, Scott John K Jr. bought 555,555 shares of the company’s stock in a deal that was recorded on Dec 06. The shares were cost at an average price of 0.90 per share, with a total market value of 500,000. Following this completion of disposal, the 10% Owner, Scott John K Jr. now holds 4,000,000 shares of the company’s stock, valued at 3,000,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 39.60%.